A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Recruiting

Phase 1

AZD6234 & AZD9550A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Sponsor:

AstraZeneca

Code:

NCT07546760

Conditions

Hepatic Impairment

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

AZD6234

AZD9550

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-20. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-05-05.